Furthermore, preliminary data from our laboratory indicate that this drug combination is also synergistic in other tumor entities in vitro, suggesting that cancer cells might be highly vulnerable to eIF4A and mTOR pathway inhibition. The gene discussed is EIF4A2; the disease is neoplasm.